Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sativex for Spasticity in Multiple Sclerosis
NCT00681538Phase 3Completed
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Jan 2008
- Primary completion
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple sclerosis (MS) comparing Sativex with Placebo (2 arms). Primary endpoint: Change in Mean Spasticity Numerical Rating Scale Score at 12 weeks. Started Jan 2008; status: completed.
02
Drugs
cannabidiol
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT00681538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00681538.